Table 1 Monoclonal antibodies and their targets
Name | Target | Study phase | Route of administration |
|---|---|---|---|
Omalizumab | IgE | Approved | Subcutaneous |
Quilizumab | IgE | IIa | Subcutaneous |
Ligelizumab | IgE | IIa | Subcutaneous |
Lumiliximab | FcϵRII (CD23) | II/III | Oral |
Daclizumab | IL2-R (CD25) | II | Intravenous |
Lebrikizumab | IL-13 | III | Subcutaneous |
Mepolizumab | IL-5 | III | Intravenous/Subcutaneous |
Reslizumab | IL-5 | III | Intravenous |
Benralizumab | IL-5 | IIb | Intravenous |
Mogamulizumab | CCR4 | III | Intravenous |
Infliximab | TNF-α | II | Intravenous |
Golimumab | TNF-α | IIa | Intravenous |
Etanercept | TNF-α (soluble receptor) | II | Subcutaneous |
Eculizumab | C5a | II | Intravenous |
Canakimumab | IL-1ß | IIb | Subcutaneous |
SNG001 (Inhaled IFN-β 1a) | IFN- β | II | Inhalation |